Dedicated to developing and commercializing treatments for cardiometabolic and oncology.

Changing the Paradigm for High-Quality Weight Loss and Oncology

Veru is focused on the development of enobosarm, a novel, oral, selective androgen receptor modulator (SARM) to address one of the most significant adverse effects, the loss of muscle, in patients undergoing weight loss therapy with glucagon-like peptide-1 (GLP-1) drugs.

The Company is also focused on the development of sabizabulin, an oral novel microtubule targeting agent that targets downstream components of the KRAS signaling pathway, as a potential next treatment for KRAS-driven metastatic pancreatic cancer that has become resistant to the recent FDA approved daraxonrasib, a multi-selective KRAS inhibitor therapy.

“We want to be there for patients undergoing GLP-1 therapy for weight loss to help avoid the side effect of muscle loss while also furthering high-quality weight loss. Our goal is to make the weight loss process as healthy as it can be, ultimately benefiting patients and making their lives better. We are also focused on advancing sabizabulin as a potential treatment for patients with metastatic pancreatic cancer that has become resistant to daraxonrasib (RASONQUE). Across both programs, our goal is to address important unmet medical needs and develop therapies that can make a meaningful difference in patients’ lives.”

— Dr. Mitchell Steiner, Veru’s Chief Executive Officer